The International Myopia Institute (IMI) has released the much-anticipated 2021 edition of white papers and yearly digest in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.
Continuing the advancement of myopia diagnosis, treatment, prevention, and public awareness, the 2021 white papers follow the first series published in 2019 through IOVS. These landmark papers are always the subject of much excitement within the vision care industry.
These landmark papers are always the subject of much excitement within the vision care industry
In the April issue of mivision, we interviewed IMI’s Executive Director Monica Jong and BHVI’s and IMI Taskforce Chair Professor Padmaja Sankaridurg to find out more about the 2021 reports.
“Myopia is estimated to affect half the world’s population by 2050. Vision impairment due to uncorrected myopia and myopia related complication is on the rise and expected to increase further,” says Professor Padmaja Sankaridurg, Chair of the IMI Impact of Myopia Taskforce and BHVI Myopia Program Leader. “BHVI and the IMI are deeply committed to disseminating the latest evidence-based myopia research for the benefit of all.”
“The original IMI 2019 white papers helped change the way clinicians thought of myopia – as an ocular condition versus a purely refractive issue – the latest IMI 2021 white papers continue to build on the evidence-base for implementing myopia management. Practitioners, researchers, industry and peak health bodies will find the IMI 2021 white papers valuable,” says Dr Monica Jong, Executive Director of the IMI. “Collaboration between all eye care stakeholders is the key to advancing research, awareness and making clinical management affordable and accessible to all children with myopia.”
The IMI 2021 white papers and yearly digest update listed below are authored by a large group of leading global experts in myopia, and present the latest research, recommendations and updates in the field.
• IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice (Chair James Wolffsohn, Aston University)
• IMI Impact of myopia (Chair Padmaja Sankaridurg, BHVI)
• IMI environmental risk factors in myopia (Chair Ian Morgan, Australian National University)
• IMI accommodation and binocular vision in myopia development and progression (Chair Nicola Logan, Aston University)
• IMI Pathologic myopia (Chair Kyoko Ohno-Matsui, Tokyo Medical and Dental University)
• IMI Prevention of myopia and its progression (Chair Jost B. Jonas, Heidelberg University)
• IMI Yearly Digest 2021 (Chairs Monica Jong, University of Canberra, and Earl Smith, University of Houston)
“High myopia will affect one billion people by 2050,” added Professor Serge Resnikoff, Chair of the IMI. “These new white papers address the impact and treatments for pathologic myopia, providing a blueprint for the way forward in tackling the myopia epidemic.”
Read the IMI 2019 white papers and clinical summaries.
Read the IMI 2021 white papers.
Read mivision’s interview with IMI’s Executive Director Monica Jong and BHVI’s and IMI Taskforce Chair Professor Padmaja Sankaridurg
The IMI 2021 clinical summaries will be available soon.